A207940 Stock Overview
Engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A207940 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Samsung Biologics Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩949,000.00 |
| 52 Week High | ₩1,113,000.00 |
| 52 Week Low | ₩721,000.00 |
| Beta | 0.33 |
| 1 Month Change | -2.67% |
| 3 Month Change | -2.87% |
| 1 Year Change | 24.87% |
| 3 Year Change | 4.17% |
| 5 Year Change | 130.34% |
| Change since IPO | 559.03% |
Recent News & Updates
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Dec 24
Samsung Biologics Co.,Ltd. (KRX:207940) Investors Are Less Pessimistic Than Expected
Nov 11These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Sep 09Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up
Jul 29Recent updates
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Dec 24Samsung Biologics Co.,Ltd. (KRX:207940) Investors Are Less Pessimistic Than Expected
Nov 11These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Sep 09Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up
Jul 29Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
May 27What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You
Apr 14Shareholder Returns
| A207940 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -1.5% |
| 1Y | 24.9% | 26.7% | -12.2% |
Return vs Industry: A207940 matched the KR Life Sciences industry which returned 24.3% over the past year.
Return vs Market: A207940 exceeded the KR Market which returned -12.2% over the past year.
Price Volatility
| A207940 volatility | |
|---|---|
| A207940 Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 10.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A207940 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A207940's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 4,744 | John Chongbo Rim | samsungbiologics.com |
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization.
Samsung Biologics Co.,Ltd. Fundamentals Summary
| A207940 fundamental statistics | |
|---|---|
| Market cap | ₩67.54t |
| Earnings (TTM) | ₩1.05t |
| Revenue (TTM) | ₩4.36t |
64.2x
P/E Ratio15.5x
P/S RatioIs A207940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A207940 income statement (TTM) | |
|---|---|
| Revenue | ₩4.36t |
| Cost of Revenue | ₩2.22t |
| Gross Profit | ₩2.14t |
| Other Expenses | ₩1.09t |
| Earnings | ₩1.05t |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.79k |
| Gross Margin | 49.10% |
| Net Profit Margin | 24.12% |
| Debt/Equity Ratio | 7.8% |
How did A207940 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:53 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Samsung Biologics Co.,Ltd. is covered by 48 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Girish Bakhru | BofA Global Research |
| Hyeryeong Kim | CGS International |
| Jun Lim | CGS International |